| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:S07-2005 (racemic)
CAS:1826337-40-9
Package:50mg/RMB 13800;25mg/RMB 10600;100mg/RMB 17500
|
3-Furancarboxylic acid, 5-[[[(6-ethoxy-3,4-dihydro-2H-1-benzopyran-3-yl)carbonyl]methylamino]methyl]-2-methyl- manufacturers
- S07-2005 (racemic)
-
- $1980.00 / 50mg
-
2025-10-27
- CAS:1826337-40-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 3-Furancarboxylic acid, 5-[[[(6-ethoxy-3,4-dihydro-2H-1-benzopyran-3-yl)carbonyl]methylamino]methyl]-2-methyl- Basic information |
| | 3-Furancarboxylic acid, 5-[[[(6-ethoxy-3,4-dihydro-2H-1-benzopyran-3-yl)carbonyl]methylamino]methyl]-2-methyl- Chemical Properties |
| Boiling point | 586.6±50.0 °C(Predicted) | | density | 1.265±0.06 g/cm3(Predicted) | | pka | 4.39±0.26(Predicted) |
| | 3-Furancarboxylic acid, 5-[[[(6-ethoxy-3,4-dihydro-2H-1-benzopyran-3-yl)carbonyl]methylamino]methyl]-2-methyl- Usage And Synthesis |
| Uses | S07-2005 racemic is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 0.13 μM and 0.75 μM for AKR1C3 and AKR1C4, respectively. S07-2005 racemic has potential as a chemotherapeutic potentiator for cancer agent resistance[1]. | | References | [1] Siyu He, et al. Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Med. Chem. Lett. Jun 2022. |
| | 3-Furancarboxylic acid, 5-[[[(6-ethoxy-3,4-dihydro-2H-1-benzopyran-3-yl)carbonyl]methylamino]methyl]-2-methyl- Preparation Products And Raw materials |
|